^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Alecsat (cytotoxic lymphocyte-based cancer vaccine)

    i
    Other names: cytotoxic lymphocyte-based cancer vaccine
    Associations

    News

    Trials
    Company:
    CytoVac
    Drug class:
    NK cell stimulant, Cytotoxic T lymphocyte stimulant
    Related drugs:
    Associations

    News

    Trials
    8d
    Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with chemotherapy in locally advanced or metastatic triple-negative breast cancer: the ImmunoBreast phase Ib clinical trial. (PubMed, J Immunother Cancer)
    ALECSAT, in combination with carboplatin and gemcitabine, was safe, well tolerated, and demonstrated promising antitumor activity in mTNBC. These findings support further investigation in larger clinical trials.
    P1 data • Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    carboplatin • gemcitabine • Alecsat (cytotoxic lymphocyte-based cancer vaccine)
    5years
    ImmunoBreast - A Phase Ib Study (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Henrik Ditzel
    Clinical • New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • HR positive • ER expression
    |
    carboplatin • gemcitabine • Alecsat (cytotoxic lymphocyte-based cancer vaccine)